This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignee: Ultragenyx Pharmaceutical Inc.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Matthew Scott Fuller: Innovator in Gene Therapy
Introduction
Matthew Scott Fuller is a notable inventor based in Millis, MA (US). He has made significant contributions to the field of gene therapy, particularly in the treatment of propionic acidemia. His innovative work has the potential to impact many lives.
Latest Patents
Matthew Scott Fuller holds a patent for "Gene Therapy for Treating Propionic Acidemia." This patent represents a crucial advancement in medical science, offering new hope for patients suffering from this rare metabolic disorder. He has 1 patent to his name, showcasing his dedication to innovation in healthcare.
Career Highlights
Fuller is currently employed at Ultragenyx Pharmaceutical Inc., a company focused on developing innovative therapies for rare diseases. His role at Ultragenyx allows him to work on groundbreaking projects that aim to improve patient outcomes.
Collaborations
Throughout his career, Matthew has collaborated with esteemed colleagues, including Stewart Craig and Samuel C. Wadsworth. These partnerships have fostered a collaborative environment that enhances the development of new therapies.
Conclusion
Matthew Scott Fuller is a pioneering inventor whose work in gene therapy is making a significant difference in the treatment of propionic acidemia. His contributions to the field exemplify the importance of innovation in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile